Author: Khamis, Faryal; Al-Zakwani, Ibrahim; Al Hashmi, Sabria; Al Dowaiki, Samata; Al Bahrani, Maher; Pandak, Nenad; Al Khalili, Huda; Memish, Ziad
Title: Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection Cord-id: 6g3obmzc Document date: 2020_6_23
ID: 6g3obmzc
Snippet: OBJECTIVES: To evaluate the therapeutic use of plasma exchange in COVID-19 patients compared to controls. METHODS: Case series of critically ill adult men and non-pregnant women, ≥18 years of age, with laboratory confirmed COVID-19, was conducted at the Royal Hospital, Oman, from April 17(th) to May 11(th), 2020. Therapeutic plasma exchange (TPE) was performed on patients admitted to intensive care unit (ICU) with confirmed or imminent acute respiratory distress syndrome (ARDS) or severe pneum
Document: OBJECTIVES: To evaluate the therapeutic use of plasma exchange in COVID-19 patients compared to controls. METHODS: Case series of critically ill adult men and non-pregnant women, ≥18 years of age, with laboratory confirmed COVID-19, was conducted at the Royal Hospital, Oman, from April 17(th) to May 11(th), 2020. Therapeutic plasma exchange (TPE) was performed on patients admitted to intensive care unit (ICU) with confirmed or imminent acute respiratory distress syndrome (ARDS) or severe pneumonia. Analysis was performed using univariate statistics. RESULTS: A total of 31 COVID-19 patients were included with an overall mean age of 51 ± 15 years (range: 27-76 years), 90% (n = 28) were males, and 35% (n = 11) of the patients had TPE as a mode of treatment. The TPE group was associated with higher extubation rates than the non-TPE cohort (73% versus 20%; p = 0.018). Additionally, patients on TPE had a lower 14 days (0 versus 35%; p = 0.033) and 28 days (0 versus 35%; p = 0.033) all-cause mortality compared to patients not on TPE. However, all-cause mortality was only marginally lower in the TPE group compared to the non-TPE group (9.1% versus 45%; p = 0.055; power = 66%). Laboratory and ventilatory parameters also improved with the TPE. CONCLUSIONS: The use of TPE in severe COVID-19 patients has been associated with improved outcomes, however, randomized controlled clinical trials are warranted to draw final conclusive findings.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and low airway: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- acute ards respiratory distress syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute ards respiratory distress syndrome and macrophage activation syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute coronary syndrome and liver kidney injury: 1, 2
- acute coronary syndrome and lung injury: 1
- acute coronary syndrome patient and lung injury: 1
- acute onset and liver kidney injury: 1
- acute onset and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute onset and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute onset and macrophage activation: 1
- acute onset and macrophage activation syndrome: 1
- acute onset hypoxemia and lung injury: 1, 2, 3
- acute respiratory infection and liver kidney injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date